Up to a third of hospitals currently participating in the 340B drug-pricing program say they would consider opting out if proposed regulatory changes are finalized, a leading advocacy group said on Wednesday.

More than a quarter of the 2,100 hospitals that participate in the drug-discount program would be significantly affected by the provisions included within the Health Resources and Services Administration’s draft omnibus guidance released in August, according to the advocacy group 340B Health.

Read more.

Want To Stay Up-To-Date On The Latest 340B News?

"*" indicates required fields